Form 4: SpringWorks Therapeutics COO Sells 30,000 Shares Under 10b5-1 Trading Plan

Badreddin Edris, Chief Operating Officer of SpringWorks Therapeutics, sold 30,000 shares of common stock at an average price of $53.1265 on February 10, 2025, according to a Form 4 filing with the SEC.

Summary

• On February 10, 2025, Badreddin Edris, the Chief Operating Officer of SpringWorks Therapeutics, sold 30,000 shares of the company's common stock.
• The sale was executed at a weighted average price of $53.1265 per share.
• The transactions were carried out under a pre-arranged trading plan established on February 29, 2024, in accordance with Rule 10b5-1.
• Following the reported transaction, Edris directly owns 189,712 shares of SpringWorks Therapeutics.
• The price range for the shares sold was between $53.00 and $53.76.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale by an executive under a pre-existing trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This filing reflects routine transactions by company insiders and is a common practice for executives to diversify their holdings or manage personal finances. The use of a 10b5-1 trading plan suggests that the sales were pre-planned and not based on any inside information.

Comparison to Industry Standards

• Executive stock sales are a common occurrence in publicly traded companies, especially in the pharmaceutical and biotechnology sectors.
• Similar transactions can be observed among executives at companies like Pfizer (PFE), Amgen (AMGN), and Bristol-Myers Squibb (BMY).
• The use of 10b5-1 trading plans is a standard practice to avoid accusations of insider trading, aligning with SEC regulations and industry best practices.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely minimal given the relatively small volume of shares sold compared to the company's total outstanding shares.
• The sale does not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

SpringWorks Therapeutics, SWTX, Badreddin Edris, Chief Operating Officer, Form 4, SEC Filing, Stock Sale, 10b5-1 Trading Plan, Insider Trading